Evaluate early-stage assets in pipeline, pharma expert says

01/14/2013 | Forbes

It is important to analyze a pharmaceutical company’s entire pipeline, not just its drugs in late-stage trials, says John LaMattina, a former Pfizer R&D president and senior partner at PureTech Ventures. The information will indicate a company's therapeutic priority areas and strategies. He says some drug companies are very transparent with information about their early-stage assets.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN